World Library  
Flag as Inappropriate
Email this Article

Biovista

Article Id: WHEBN0018713130
Reproduction Date:

Title: Biovista  
Author: World Heritage Encyclopedia
Language: English
Subject: Drug repositioning, Adverse event prediction, Aderis Pharmaceuticals, ARYx Therapeutics, Zonite Products Corporation
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Biovista


Biovista, Inc.
Private
Industry Biotechnology
Founded Charlottesville, VA, USA (2005)
Headquarters Charlottesville, VA, USA
Services Drug repositioning
Slogan To Seek, To know, To Act
Website www.biovista.com

Biovista Inc. is a private drug development services company based in Charlottesville, Virginia, USA. Biovista's core business activities include Drug repositioning and drug de-risking as well as disease cohort analysis, adverse event prediction and clinical hold analysis services. Biovista is also applying its technology platform to develop its own drug repositioning programs in the areas of central nervous system (CNS), diabetes/obesity, eye disorders, and oncology.

Biovista is an active participant of European Union co-funded R&D projects spanning areas such as post-genomic clinical trials research (ACGT project), mutant mouse models for the investigation of Human Immunological Disease (MUGEN project), semantic annotation and ontology driven text mining (PARMENIDES project) and systematic knowledge discovery (ESPERONTO Project).

Technology

The company derisks and repositions drugs using multidimensional profiles of pharmacologically relevant entities such as genes, diseases, drugs, pathways and cell types, to identify and rank potential adverse events and new indications for drugs in development, on the market, or generics.

Biovista is also creating software-based tools and services for Reagent companies, researchers in the Life sciences and the consumer and patient health areas.

Biovista's technology platform is based on the analysis and integration of Biomedical information available in the scientific literature using Biomedical text mining techniques. Pharmacologically-relevant areas include drug toxicity, drug mode of action, disease mechanisms and biological system interactions. Biovista Inc.’s technology platform integrates literature-based discovery algorithms with Semantic search technologies to identify and rank potential solutions to a variety of drug development related problems such as predicting the adverse events of compounds, identifying suitable biomarkers for diseases and discovering new indications for existing drugs or drug combinations.

Biovista’s correlation engine scans potential interactions between pharmacologically relevant entities resulting in a correlation database. The database itself is based on a proprietary design that combines the Relational database management system (RDBMS) model with the Object-Oriented model allowing researchers to obtain preliminary answers in weeks rather than years.

In January 2010, Biovista announced that the U.S. Food and Drug Administration (FDA) has licensed its technology platform to help analyze, identify, and better understand the way certain drugs can cause harmful side effects. Since the beginning of 2009, Biovista has started its own drug development programs based on repositioned compounds in CNS diseases, such as Multiple sclerosis and Epilepsy.

References

  1. ^ http://www.prnewswire.com/news-releases/biovista-inc-and-fda-to-collaborate-on-a-medication-safety-initiative-81222007.html
  2. ^ http://www.drugs.com/clinical_trials/biovista-inc-announces-positive-efficacy-results-pre-clinical-trial-bva-101-repositioned-multiple-6964.html
  3. ^ http://www.news-medical.net/news/20090910/Biovistas-BVA-201-drug-for-MS-shows-positive-results.aspx
  4. ^ http://www.asia-lifesciences.com/news-86-bva601-biovistainc-preclinicaltrial-epilepsy-news5.html
  5. ^ ACGT European Project
  6. ^ MUGEN European Project
  7. ^ PARMENIDES European Project
  8. ^ ESPERONTO European Project

External links

  • Official website
  • European Medicines Agency (EMEA)
  • HUM-MOLGEN Registry of biomedical companies
  • Pharmalicensing Registry of biomedical companies
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.